Division of Innovative Research and Development Advanced Research & Development Programs for Medical Innovation(AMED-CREST, PRIME)

Understanding proteostasis and discovering innovative medical applications

[Research and Development Objective]Understanding and medical application of proteostasis

This R&D area aims to clarify the relationship between structure and function based on evidence obtained from biochemical and structural biological approaches, to understand the molecular pathways that cause various diseases, and to discover potential solutions for healthcare or methods to maintain good health.
The R&D is focused on understanding the molecular basis of proteins during the processes that occur between initial protein translation and synthesis to ultimate degradation, and will investigate denaturation, aggregation, and degradation processes that set proteins on a final, irreversible pathway, as well as posttranslational modifications that have irreversible effects on protein function.

Target diseases include, but are not limited to, neurodegenerative disease, mental health disorders, intractable cancers, chronic inflammatory diseases, amyloidosis, fibrosis, rare diseases, infectious diseases, and lifestyle diseases like arteriosclerosis and diabetes, as well as insights into how to avoid aging and maintain a healthy state.As well as researchers involved in the fields of proteins and glycans, we welcome participation by basic science or clinical researchers in structural biology, immunity, metabolism, or nerve systems, as well as researchers from other fields, including analytical chemistry and bioinformatics.

The goal is to make progress in world-class, highly innovative research and development by bringing together and leveraging the strengths of a range of disciplines.

2020

Program Supervisor (PS)

NAGATA Kazuhiro

Director General, JT Biohistory Research Hall

Program Officer (PO)

KATO Koichi

Professor, Exploratory Research Center on Life and Living Systems, National Institutes of Natural Sciences

R&D Area Advisors

ADACHI Takeshi

Professor, School of Medicine, National Defense Medical College

INADA Toshifumi

Professor, The Institute of Medical Science, The University of Tokyo

IWAI Kazuhiro

Provost, Executive Vice-President, Kyoto University

KINOSHITA Taroh

Professor, Research Institute for Microbial Diseases, Osaka University

SHIMIZU Ritsuko

Professor, Tohoku University School of Medicine

SUZUKI Rami

Representative Director and CEO, ARC Therapies Inc.

FUJIMOTO Toyoshi

Research Professor, Juntendo University School of Medicine

MIYOSHI Eiji

Professor, Graduate School of Medicine, Osaka University

YAMADA Hisafumi

Former Executive Vice President, Chugai Pharmaceutical Co., LTD.

Last updated 04/16/24